KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $28.5 million.

  • Resmed's Capital Expenditures rose 3824.36% to $28.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $122.9 million, marking a year-over-year increase of 4532.97%. This contributed to the annual value of $89.9 million for FY2025, which is 964.71% down from last year.
  • Resmed's Capital Expenditures amounted to $28.5 million in Q4 2025, which was up 3824.36% from $43.0 million recorded in Q3 2025.
  • Resmed's 5-year Capital Expenditures high stood at $48.4 million for Q1 2022, and its period low was $17.8 million during Q3 2024.
  • For the 5-year period, Resmed's Capital Expenditures averaged around $28.5 million, with its median value being $28.2 million (2021).
  • In the last 5 years, Resmed's Capital Expenditures crashed by 4060.26% in 2024 and then skyrocketed by 14083.52% in 2025.
  • Quarter analysis of 5 years shows Resmed's Capital Expenditures stood at $30.4 million in 2021, then decreased by 10.05% to $27.4 million in 2022, then decreased by 14.61% to $23.4 million in 2023, then fell by 11.6% to $20.6 million in 2024, then soared by 38.24% to $28.5 million in 2025.
  • Its Capital Expenditures was $28.5 million in Q4 2025, compared to $43.0 million in Q3 2025 and $30.6 million in Q2 2025.